Advertisement
UK markets close in 8 hours 2 minutes
  • FTSE 100

    8,070.31
    +46.44 (+0.58%)
     
  • FTSE 250

    19,641.79
    +42.40 (+0.22%)
     
  • AIM

    750.03
    +0.85 (+0.11%)
     
  • GBP/EUR

    1.1582
    -0.0007 (-0.06%)
     
  • GBP/USD

    1.2355
    +0.0005 (+0.04%)
     
  • Bitcoin GBP

    53,730.46
    +173.79 (+0.32%)
     
  • CMC Crypto 200

    1,399.08
    -15.68 (-1.11%)
     
  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     
  • DOW

    38,239.98
    +253.58 (+0.67%)
     
  • CRUDE OIL

    83.02
    +0.17 (+0.21%)
     
  • GOLD FUTURES

    2,320.10
    -26.30 (-1.12%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,798.03
    +286.34 (+1.73%)
     
  • DAX

    18,017.70
    +156.90 (+0.88%)
     
  • CAC 40

    8,074.62
    +34.26 (+0.43%)
     

How Cosentyx Resolves Enthesitis in Psoriatic Arthritis Patients

How Cosentyx Resolves Enthesitis in Psoriatic Arthritis Patients

Novartis: What Are the Major Growth Drivers for 2018? On November 14, 2016, Novartis (NVS) announced positive results from the Phase 3 pivotal study, FUTURE 1. This study highlighted the efficacy of Cosentyx in providing sustained benefit over three years in psoriatic arthritis patients.